Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

VCU-led research highlights semaglutide’s potential for treating fatty liver disease Provided by GlobeNewswire Apr 30, 2025, 10:09:48 PM ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Advances such as triple agonists, gene editing, and microbiome therapy offer hope for metabolic diseases, but global access and early detection remain limited.

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

MASH, a progressive form of fatty liver disease, is marked by liver inflammation, hepatocyte injury, and fibrotic changes. Left untreated, it can lead to cirrhosis, liver failure, and ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.